NCT07364474

Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver

Evaluating Immune Response to Percutaneous Hepatic Perfusion With Melphalan for the Treatment of Ocular Melanoma Metastatic to the Liver

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Massachusetts General Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study seeks to better understand the liver's immune response to receiving chemotherapy agent melphalan through Percutaneous Hepatic Perfusion (PHP) for patients with Uveal Melanoma that has metastasized to the liver.

Detailed description

Biopsies and blood samples will be collected before treatment to establish baseline measurements. Patients will then receive a single dose of Melphalan via Percutaneous Hepatic Perfusion (PHP) and return 21-28 days later for a follow-up biopsy and peripheral blood draw. Baseline and post-treatment samples will be compared to evaluate the immune response.

Conditions

• Uveal Melanoma

Interventions

Type	Name	Description
DRUG	Melphalan through Percutaneous Hepatic Perfusion	Melphalan through Percutaneous Hepatic Perfusion will be received as standard of care,

Timeline

• Start date: 2026-01-27
• Primary completion: 2027-12-01
• Completion: 2028-09-01
• First posted: 2026-01-23
• Last updated: 2026-03-11

Locations

1 site across 1 country: United States